Part B: Supplementary Information Sheet (SIS) |
FR Recognition List Number
|
021
|
Date of Entry 03/18/2009
|
FR Recognition Number
|
7-182
|
Standard | |
CLSI M36-A Clinical Use and Interpretation of Serologic Tests for Toxoplasma gondii; Approved Guideline. |
|
Scope/AbstractThis guideline provides the user with information about the biology of Toxoplasma gondii, the methods available for use in the laboratory diagnosis of human toxoplasmosis, techniques that should be performed for specific clinical situations, and how to interpret laboratory results. |
|
Extent of Recognition
|
Public Law, CFR Citation(s) and Procode(s)*
Regulation Number |
Device Name |
Device Class |
Product Code |
§866.3780 |
Antigens, If, Toxoplasma Gondii
|
Class 2
|
GLZ
|
§866.3780 |
Antigens, Iha, Toxoplasma Gondii
|
Class 2
|
GMM
|
§866.3780 |
Antigens, Cf, Toxoplasma Gondii
|
Class 2
|
GMN
|
§866.3780 |
Enzyme Linked Immunoabsorbent Assay, Toxoplasma Gondii
|
Class 2
|
LGD
|
§866.3780 |
Antisera, If, Toxoplasma Gondii
|
Class 2
|
LJK
|
§866.3780 |
Direct Agglutination Test, Toxoplasma Gondii
|
Class 2
|
LLA
|
§866.3780 |
Pneumocystis Carinii
|
Class 2
|
LYF
|
|
Relevant FDA Guidance and/or Supportive Publications*
Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices - Guidance for Industry and Food and Drug Administration Staff, issued September 2018. |
|
FDA Technical Contact
|
Standards Development Organization
|
FDA Specialty Task Group (STG)
|
*These are provided as examples and others may be applicable. |